Looking for a new broker?
Achilles Therapeutics plc stock is up 12.49% since 30 days ago. The next earnings date is Mar 5, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 December’s closed higher than November.
Achilles Therapeutics Plc develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; THETIS, a product candidate in clinical trials for use of metastatic or recurrent melanoma. Achilles is headquartered in London, the United Kingdom.
